Dow Jones

40,003.59

0.34%

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

Inicio
Invertir
Acciones
Estados Unidos
NASDAQ
Oramed Pharmaceuticals Inc (ORMP)
Oramed Pharmaceuticals Inc (ORMP) Noticias

ORMP

Oramed Pharmaceuticals (ORMP)

Oramed Pharmaceuticals Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ORMP

1 2 3 4 5 6 7 8 9 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
09/05/2024	16:00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
06/05/2024	08:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
19/03/2024	08:00	GlobeNewswire Inc.	Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
06/03/2024	16:00	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
20/02/2024	07:30	PR Newswire (US)	Oramed Letter to Shareholders	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
30/01/2024	16:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
02/01/2024	12:13	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
22/09/2023	10:38	PR Newswire (US)	Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
21/09/2023	17:11	PR Newswire (US)	Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
21/09/2023	15:05	GlobeNewswire Inc.	Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
13/09/2023	08:00	GlobeNewswire Inc.	Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
02/08/2023	06:45	PR Newswire (US)	Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
20/06/2023	06:55	PR Newswire (US)	Oramed to Present at the 83rd American Diabetes Association Conference	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
18/05/2023	06:55	PR Newswire (US)	Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
15/05/2023	08:05	PR Newswire (US)	Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
11/05/2023	16:02	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
01/05/2023	16:08	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
01/05/2023	15:53	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
01/05/2023	15:45	PR Newswire (US)	Oramed Appoints Ben Shapiro to its Board of Directors	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
20/04/2023	05:05	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
09/02/2023	06:55	PR Newswire (US)	Oramed Pharmaceuticals Issues Shareholder Update	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
11/01/2023	19:00	PR Newswire (US)	Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
04/01/2023	06:55	PR Newswire (US)	Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
29/11/2022	07:40	PR Newswire (US)	Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
18/11/2022	04:43	TipRanks	Oramed Pharma Up After Positive Clinical Data	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
17/11/2022	11:26	PR Newswire (US)	Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
14/11/2022	06:55	PR Newswire (US)	Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
10/11/2022	15:30	PR Newswire (US)	Oramed Reports Third Quarter 2022 Financial Results	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
09/11/2022	07:40	PR Newswire (US)	Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH	NASDAQ:ORMP	Oramed Pharmaceuticals Inc
07/10/2022	07:40	PR Newswire (US)	Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine	NASDAQ:ORMP	Oramed Pharmaceuticals Inc